- Home
- ELVN vs TRS Comparison
ELVN vs TRS Comparison
Compare ELVN & TRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELVN
- TRS
- Stock Information
- Founded
- ELVN 2016
- TRS 1986
- Country
- ELVN United States
- TRS United States
- Employees
- ELVN N/A
- TRS N/A
- Industry
- ELVN Biotechnology: Pharmaceutical Preparations
- TRS Industrial Specialties
- Sector
- ELVN Health Care
- TRS Industrials
- Exchange
- ELVN Nasdaq
- TRS Nasdaq
- Market Cap
- ELVN 1.1B
- TRS 985.7M
- IPO Year
- ELVN 2020
- TRS 2007
- Fundamental
- Price
- ELVN $21.00
- TRS $24.25
- Analyst Decision
- ELVN Strong Buy
- TRS Strong Buy
- Analyst Count
- ELVN 5
- TRS 1
- Target Price
- ELVN $37.80
- TRS $40.00
- AVG Volume (30 Days)
- ELVN 213.5K
- TRS 560.0K
- Earning Date
- ELVN 03-17-2025
- TRS 04-29-2025
- Dividend Yield
- ELVN N/A
- TRS 0.66%
- EPS Growth
- ELVN N/A
- TRS N/A
- EPS
- ELVN N/A
- TRS 0.59
- Revenue
- ELVN N/A
- TRS $925,010,000.00
- Revenue This Year
- ELVN N/A
- TRS $6.34
- Revenue Next Year
- ELVN N/A
- TRS $3.39
- P/E Ratio
- ELVN N/A
- TRS $41.10
- Revenue Growth
- ELVN N/A
- TRS 3.52
- 52 Week Low
- ELVN $10.90
- TRS $19.33
- 52 Week High
- ELVN $30.03
- TRS $28.51
- Technical
- Relative Strength Index (RSI)
- ELVN 47.82
- TRS 59.41
- Support Level
- ELVN $18.67
- TRS $19.33
- Resistance Level
- ELVN $22.36
- TRS $21.33
- Average True Range (ATR)
- ELVN 1.07
- TRS 0.95
- MACD
- ELVN 0.06
- TRS 0.20
- Stochastic Oscillator
- ELVN 60.84
- TRS 98.60
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage precision oncology company focused on the discovery and development of potentially first-in-class precision oncology therapies. Enliven's programs are designed to address issues such as tolerability, combinability, resistance and disease escape through brain metastases. Its product candidates include ELVN-001 which is a potent, selective, small molecule kinase inhibitor designed to specifically target the BCR-ABL gene fusion, the oncogenic driver for patients with chronic myeloid leukemia, and the ELVN-002 which is central nervous system (CNS) penetrant and irreversible HER2 inhibitor with activity against wild type HER2 and various HER2 mutations.
About TRS TriMas Corporation
TriMas Corp is a United States-based company that designs, manufactures, and distributes engineered and applied products. The company operates through three segments namely: The packaging segment manufactures and distributes closure and dispensing systems. The aerospace segment supplies blind bolts, fasteners, rivets, and other products for the aerospace industry. The specialty product segment manufactures and distributes steel cylinders, wellhead engines, compression systems, industrial sealing, and fasteners.